Anti-tuberculosis drug resistance in new and previously treated pulmonary tuberculosis cases in Burkina Faso

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 11, 2010, Pages 1424-1429

  Sangaré, Lassana ^a,b   Diande S ^b,c   Badoum, G ^a,b   Dingtoumda, B ^c   Traore, A S ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE YALGADO OUÉDRAOGO   (Burkina Faso)

^b UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

^c Programme National de Lutte Antituberculeuse   (Burkina Faso)

Author keywords

Burkina Faso; Mycobacterium tuberculosis; Resistance; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BURKINA FASO; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; BURKINA FASO; CHILD; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 78049429719     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367: 938-940.
2. World Health Organization. The WHO/The Union Global-Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Report no. 3. WHO/CDS/TB/2004.343:1-129. Geneva, Switzerland: WHO, 2004.
3. Kuaban C, Bercion R, Jifon G, et al. Acquired anti-tuberculosis drug resistance in Yaounde, Cameroon. Int J Tuberc Lung Dis 2000; 4: 427-432. (Pubitemid 30256845)
4. Warndorff D K, Yates M, Ngwira B, et al. Trends in antituberculosis drug resistance in Karonga, Malawi, 1986-1998. Int J Tuber Lung Dis 2000; 4: 752-757.
5. Owusu-Dabo E, Adjei O, Meyer C, et al. Mycobacterium tuberculosis drug resistance, Ghana. Emerg Infect Dis 2006; 12: 170-172.
6. Ben Amor Y, Nemser B, Singh A, et al. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg Infect Dis 2008; 14: 1345-1348.
7. Petroff S A. A new and rapid method for the isolation and cultivation of tubercle bacilli directly from the sputum and feces. J Exp Med 1915; 21: 38-42.
8. El Helali N, Vergez P. Identification des mycobactéries. Feuillets de Biologie, 1993; XXXIV: 5-19. [French]
9. Canetti G, Rist N, Grosset J. Mesure de la sensibilité du bacille tuberculeux aux drogues antibacillaires par la méthode des proportions. Rev Tuberc Pneumol 1963; 27: 217-272. [French]
10. Joint United Nations Programme on HIV/AIDS (UNAIDS)-WHO. Revised recommendations for the selection and use of HIV antibody tests. Wkly Epidemiol Rec 1997; 72: 81-87.
11. Affolabi D, Adjagba O A B G, Tanimomo-Kledjo B, Gninafon M, Anagonou S Y, Portaels F. Anti-tuberculosis drug resistance among new and previously treated pulmonary tuberculosis patients in Cotonou, Benin. Int J Tuberc Lung Dis 2007; 11: 1221-1224.
12. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
13. Holmes C B, Hausler H, Nunn P. A review of sex differences in the epidemiology of tuberculosis. Int J Tuberc Lung Dis 1998; 2: 96-104.
14. Kouassi B, Horo K, N'Douba K A, et al. Profil épidé miologique et microbiologique des malades tuberculeux en situation d́chec ou de rechute à Abidjan. Bull Soc Exot 2004; 97: 336-337. [French]
15. Boulahbal F, Chaulet P. La tuberculose en Afrique, épidé miologie et mesure de lutte. Med Trop 2004; 64: 224-228. [French]
16. World Health Organization. TB country file: Burkina Faso. Geneva, Switzerland: WHO, 2009. http://apps.who.int/globalatlas/predefinedreports/tb/ PDF-Files/bfa.pdf Accessed August 2010.
17. Umubyeyi A N, Rigouts L, Zissis G, et al. Résistance primaire et acquise aux antituberculeux des souches de Mycobacterium tuberculosis isolées au Rwanda. Med Trop 2007; 67: 149-153. [French]
18. World Health Organization. Anti-tuberculosis resistance in the world. Report no. 4. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
19. Asiimwe B B, Ghebremichael S, Kallenius G, Koivula T, Joloba M L. Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in periurban Kampala, Uganda. BMC Infect Dis 2008; 8: 101.
20. Enarson D A, Rieder H L, Arnadottir T, Trébucq A. Management of tuberculosis: guide for low-income countries, 5th ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 2000.
21. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1554-1556.
22. Zager E M, McNerney R. Multidrug-resistant tuberculosis. BMC Infect Dis 2008; 8: 10.
23. Laserson K F, Wells C D. Reaching the targets for tuberculosis control: the impact of HIV. Bull World Health Organ 2007; 85: 377-386.